Please login to the form below

Not currently logged in
Email:
Password:

Digital intelligence blog

Pharma insight on digital marketing, social media, mobile apps, online video, websites and interactive healthcare tools

Takeda explores the potential of ‘digital biomarkers’

Collaborates with Mindstrong Health on mental health research

Takeda

Takeda is exploring the potential of ‘digital biomarkers’ to help develop new mental health treatments, with a particular focus on schizophrenia and treatment-resistant depression.

The firm is collaborating with Mindstrong Health, whose digital phenotyping platform continuously measures brain function from passively collected smartphone data.

Emiliangelo Ratti, head of Takeda’s Neuroscience Therapeutic Area Unit, said: "Mental health disorders are complex, multifaceted conditions, and drug development in this area of unmet need is slow to progress.

"This partnership with Mindstrong Health exemplifies Takeda's motivation to engage in digital technologies to improve the clinical assessment of patients with mental health conditions who lack adequate treatment options."

Dr Paul Dagum, founder and CEO of Mindstrong Health, added: "Takeda shares our goal of using innovative technology to gain insights that will improve outcomes for people living with mental health conditions.

"We are pleased to partner with them to implement digital technology in the clinical development of novel assets and, hopefully, allow for faster delivery of meaningful therapies to patients."

The companies hope that by joining forces they will be able to develop novel therapeutic interventions by applying digital biomarkers to stratify mental health conditions and predict remission.

6th March 2018

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

APAC map
Pharmaceutical innovation in the APAC region
A first-of-its-kind study paints a vivid picture of the APAC region’s future...
Patient journey mapping: exploring the clinical and the emotional journey
By Chris Hodgson, Neil Rees, Sumira Riaz and Karen Petticrew While we can all agree that the value of developing a patient journey map cannot be underestimated when exploring the...
Precision medicine at Blue Latitude Health
At Blue Latitude Health we have identified 90+ insights about commercialising precision medicines. Check out our video to get a run down on three core components of the commercialisation and...

Infographics